Home/ESMO Highlights 2022 in Gynecological Cancer: Are we curing ovarian cancer patients?

ESMO Highlights 2022 in Gynecological Cancer: Are we curing ovarian cancer patients?

This year`s congress provided overall survival (OS) results from the SOLO-1/GOG 3004 and PAOLA-1/ENGOT-ov25 trials investigating olaparib (ola) alone and in combination with bevacizumab (bev) as maintenance therapy in patients with advanced ovarian cancer (AOC). Based on the results of randomized phase 3 trials, Poly(adenosine diphosphate-ribose) pol-ymerase inhibitors (PARPi) have been approved as a new standard of care in AOC and have revolutionized the way patients are treated in the front-line (1–4) and recurrent setting (5–7). Currently, ola, niraparib, ola plus bev and bev demonstrated significant improvements in progression-free survival (PFS) and are approved for first-line maintenance therapy (1, 3, 4, 8)

Bich Doan Nguyen-Sträuli17.3.20232"
image

Anmelden und kostenlos alle Tools nutzen

Entdecken Sie das gesamte Angebot (z.B. Scores, Guidelines, Veranstaltungen, Drugshortages, Cochrane Library, Compendium)

Rosenbergstrasse 115
8212 Neuhausen am Rheinfall
Telefon: +41 52 675 51 74
info@docinside.ch
www.docinside.ch

Handelsregistereintrag
Firmenname: DOCINSIDE AG
UID: CHE-412.607.286

Über uns
Bankverbindung

Schaffhauser Kantonalbank
8200 Schaffhausen
IBAN: CH76 0078 2008 2797 0810 2

Mehrwertsteuer-Nummer
CHE-412.607.286

Kontakte

Dr. med. Adrian Müller
Betrieb und Inhalte
adrian.mueller@docinside.ch

Dr. med. Richard Altorfer
Inhalte und Redaktion
richard.altorfer@docinside.ch

Dr. med. Christine Mücke
Inhalte und Redaktion
christine.muecke@docinside.ch

Copyright © 2021 Alle Rechte vorbehalten.
Powered by Deep Impact / Spectra